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1. Introduction  
New Psychoactive Substances (NPS) are a group of drugs that are designed to replicate the 
effects of other illegal substances. People use them for experimental, recreational purposes and 
some may become dependent on them. NPS usually fall into one of the following four categories: 
Synthetic cannabinoids (SC), Depressants, Stimulants, and Hallucinogens. They present a 
challenge due to the significant variation in substances and perceptions of legal status.  
 
Due to the increase of NPS use in secure environments Public Health England (PHE) 
and partners have developed a toolkit providing information about NPS use in secure 
custodial settings. This provides information on the extent of use of NPS and how this 
can be effectively managed.  
 
The NHS England Mental Health Programme of Care Board identified the need for a 
similar review on the impact of NPS in secure mental health settings. PHE have led this 
review on behalf of the board. This document summarises the outputs of the review 
and makes recommendations and next steps for the management of NPS use in 
secure mental health settings.  
 
 
2. Methods 
In order to conduct this review an NPS Working Group was convened. The terms of 
reference for the group are included as Appendix 1. The remit for the group was to 
provide strategic direction for the review across organisations involved in the 
commissioning and provision of secure mental health and substance misuse services. 
The review itself consisted of two main elements; a questionnaire to service providers 
and an evidence review.  
NPS Service Provider Questionnaire 
A questionnaire was used to gain a more robust estimation on the scale of the impact 
of NPS for secure mental health settings. The aim was to develop an understanding of 
what support might be useful for the management of NPS in secure mental health 
settings. The questionnaire gathered information on the prevalence of people using 
NPS and related clinical symptoms alongside the wider impact of NPS in care settings.  
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The questionnaire was developed with input from the NPS Working Group, and this 
group was used to validate the content of the questionnaire prior to circulation. An 
online link to the questionnaire was circulated via commissioning networks to secure 
mental health units between 6th January and 21st February 2017. A copy of the 
questionnaire is included within Appendix 2.  
Responses to the completed questionnaires were collated. Descriptive analysis was 
undertaken for the quantitative responses and thematic analysis was undertaken for 
the responses to the qualitative questions. 
NPS in Secure Mental Health Setting Evidence Review 
An evidence review was conducted to identify published literature that would 
summarise impact NPS use is having on secure mental health settings; both in terms of 
the scale of the problem (prevalence of NPS use) and the clinical and managerial 
impact this has on services. A systematic literature search of peer reviewed 
publications was conducted, the details of the search strategy are included within 
Appendix 3.  
Once papers were identified through the search strategy the titles, abstracts and full 
texts were screened for relevance and those remaining papers meeting the search 
criteria were included within the evidence review.  
Thematic analysis was conducted for the papers included in the review to identify the 
key areas for discussion. The outcomes of the included papers were also considered 
against the primary and supplementary research questions. 
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Results  
Results from the Questionnaire Feedback 
66 units responded to the questionnaire representing a total of 1781 current patients. 
The recorded prevalence of current NPS use within the units that responded was 
relatively low (1.1%), however the reported prevalence of use by patients prior to 
admission to the unit was higher (12.1%). Details of the prevalence by unit type can be 
found in Appendix 2. Regarding the impact of NPS use on cause of admission 44 of the 
66 units responding reported that they had at least one patient in the past 12 months 
where NPS was a causal or contributory factor for admission. Synthetic cannabinoids 
were the most commonly reported NPS in use, followed by stimulants. Reported use of 
depressants and hallucinogens were much lower. Two thirds of those recorded as 
using NPS were also recorded as using at least one other illicit substance.  
Regarding the symptoms associated with NPS use, the most frequently associated 
physical symptoms were cardiovascular symptoms, reduced consciousness, dizziness 
and vomiting. The most frequently associated psychological symptoms were psychosis, 
anger, aggression and paranoia.  
Across the 66 units that responded, 14 reported that they had required an emergency 
response to assist with NPS use in the last 12 months; this represented 52 reported 
incidents. Reasons for these acute responses were related to emergency treatment for 
NPS induced physical and psychological symptoms such as collapse, cardiovascular 
symptoms and acute exacerbations of existing mental health conditions.  
Regarding the wider impact of NPS on the culture within mental health settings units 
reported the following challenges; impacts on staff resources, trading and exploitation, 
perception of those using NPS by non-users, violence, ability to test for NPS and 
impact on leave. Additional challenges noted by the units were; bullying and 
safeguarding, concerns about impacts on treatment and concerns about the impact on 
the physical health of service users.  
Respondents to the questionnaires identified the following areas where they feel they 
could benefit from additional support to improve the management of people using NPS; 
staff training, service user information, testing for NPS, information on specific 
substances, additional national guidance and opportunities to share learning with other 
units. 
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Evidence Review Results  
24 papers met the search criteria for inclusion in the evidence review. However the 
quality of the study types available was limited to case reports, clinical audits and case 
note audits (n = 10), with only 2 systematic literature reviews meeting the search 
criteria. Therefore the validity of the finding and generalisability of the results in practice 
are limited. The review was however able to identify a number of themes relevant to the 
impact of NPS in secure mental health services. A detailed summary of results of the 
evidence review is included in Appendix 3.  
The results from the review indicate that NPS can induce psychiatric symptoms in 
those with no prior mental health diagnosis and can exacerbate symptoms in those with 
existing serious mental illness. This may translate to an impact on admissions and care 
in secure mental health settings, including longer inpatient stays. However, due to the 
small number of studies available further research may need to be undertaken to 
determine the population wide impact of NPS induced mental illness, in particular the 
longer term impacts on mental health.  
The findings from the review recommend that clinicians, specifically those in 
emergency department and acute mental health settings, are aware of the potential for 
NPS to induce mental health symptoms and how this can be diagnosed and treated.  
The evidence in the included studies was limited with regards to mechanisms for the 
effective management of people using NPS in secure mental health settings. Overall 
the papers included within this study did not adequately address this question. This is 
an area that would benefit from further primary research, specifically in relation to non-
pharmacological methods for management and whether this differs from treatment for 
other illicit substances. 
The findings from the review indicate that patients should be educated about the 
psychological and other harms of using NPS and a culture of self-reporting of NPS use 
should be fostered in order to assist treatment.  
This evidence review has highlighted that, perhaps due to the emerging nature of the 
subject, limited evidence is available in this field. Further research would be 
recommended to beter address the research question.  
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3. Conclusions 
The feedback from the questionnaire has confirmed that NPS use is an issue that 
affects secure mental health units, both with regards to current use within the units and 
as a potential contributing factor for admission to the units. This potential for NPS to be 
a contributing factor for admissions to the unit is supported by published literature.  
The evidence review identifies that further information needs to be provided about the 
acute psychological symptoms associated with NPS use. Both for clinicians to ensure 
appropriate diagnosis and treatment and members of the public so that they are 
informed of the risks associated with NPS use.  
Feedback from service providers also indicates that psychological and physical 
symptoms associated with NPS use have an impact on the care of service users, in 
particular in relation to staffing resources and the management of acute incidents. Units 
have reported challenges in relation to being able to identify those using NPS and 
tensions between users and non-users within the unit. Issues have also been identified 
in relation to financial exploitation, allocation of leave, interference with treatment and 
safeguarding of vulnerable patients. The outputs from the evidence review also support 
that NPS use may have an impact on the physical health of those in secure mental 
health care.  
Further research would be beneficial to determine the impact of NPS use on secure 
mental health settings and to recommend evidence based methods for management of 
associated psychological symptoms. 
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4. Recommendations  
The following recommendations are made from the outputs of this review:  
 There is a need for additional guidance and training on the management of 
people using NPS specifically in secure mental health settings. This should build 
on the exisiting guidance developed for prisons by PHE, which has been subject 
to national evaluation. Guidance for secure mental health units should include: 
identification of those using NPS, information on the types of NPS in circulation, 
information on symptoms associated with NPS use and withdrawal from NPS 
and information on how to manage people with acute reactions to NPS.  
 There is a need to develop information resources about the risks associated with 
NPS use for service users within secure mental health settings. These should be 
in a format appropriate to service users.  
 There is a need to educate wider clinical staff, including emergency department 
staff, about the acute mental health symptoms associated with NPS use.  
 Mechanism for testing for NPS use within secure mental health settings should 
be explored to understand the impact this would have on identification and 
management.  
 Mechanisms to share best practice on the management of NPS use should be 
facilitated between secure mental health units.  
 As evidence related the impact of NPS for mental health services is an emerging 
field additional research would be welcomed in a number of areas. Findings from 
this review have identified the following as potential primary research questions:  
o Has the use of NPS led to an increase in mental health prevalence at a 
population level? 
o Does the use of NPS lead to the development of chronic mental illness?  
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o Have NPS induced psychiatric symptoms led to an increase in activity in 
secure mental health settings?  
o What are the recommended treatment options for NPS use in secure 
mental health settings? (to include supportive and pharmacological 
approaches to treatment) 
5. Next steps 
The NHS England Mental Health Programme of Care Board and Adult Secure Clinical 
Reference Group have agreed the following actions to develop the recommendations 
detailed in this report: 
 To share the recommendations for further research with NIHR contacts within 
Clinical Reference Groups.  
 Convene a stakeholder event for Autumn 2017. The event would aim to: 
o Share the findings of this report; 
o Share the findings of existing work undertaken in prisons where 
knowledge would be transferrable to a secure mental health setting;  
o Allow staff to share best practice examples between mental health units;  
o Begin to develop a package of training and guidance for the management 
of NPS use in secure mental health settings.  
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Appendix 1: Terms of Reference New 
Psychoactive Substances in Secure Mental 
Health Settings Working Group 
Aims 
The aims of this group, a partnership between PHE and NHS England (NHSE), are: 
 To describe the prevalence of NPS use in secure mental health settings. 
 To understand the number of admissions to secure mental health settings where NPS 
use is a causal or contributing factor. 
 To understand the issues faced by staff in the management of NPS use in patients in 
secure mental health settings including secure Child and Adolescent Mental Health 
Services (CAMHS).  
 To summarise the evidence related to the effective management of NPS use in secure 
mental health settings.  
 To inform current guidance on the management of NPS use in secure mental health 
settings.  
 To disseminate evidence related to the effective management of NPS in secure mental 
health settings to commissioners and providers of the service. 
 
Terms of Reference 
The group will lead a review on the scale of impact and management of NPS in secure mental 
health settings. This will include: 
 Assessing the current situation regarding the management of NPS in secure mental 
health settings to identify the nature of policies and extent to which these are 
implemented effectively. This will be done through the use of surveys and qualitative 
interviews.  
 Quantifying the prevalence of NPS use in all secure mental health settings; low, medium 
and high secure including CAMHS. The review will consider the impact of NPS on the 
whole pathway of care for this population group including referral into the service and 
impacts for onward care. 
 Reviewing the latest available published data (if relevant) on the management of NPS in 
secure mental health or comparable settings, and make recommendations on areas for 
further research. 
 Disseminating the existing evidence on effective interventions and information on 
prevalence through the development of a NPS toolkit that can be used by 
commissioners and providers of secure mental health services. 
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 Using understanding gained from the evidence reviews to initiate next steps, with the 
intention of providing supportive materials for secure mental health commissioners and 
providers in promoting an NPS free environment, supporting staff in understanding their 
roles in supporting people who use NPS and facilitating effective services to manage 
the wider impact of NPS in secure MH settings. 
 Providing a summary report to the Mental Health Programme of Care Board 
 
Membership 
In order to undertake this review a working group will be convened with clinical and operational 
expertise. The membership of the group is in development. 
Frequency of meetings 
Monthly, from November 2016. 
Reporting and Governance 
The group will report to the NHSE Programme of Care Board for Mental Health 
 
Appendix 2: A Review of New Psychoactive 
Substances in Secure Mental Health Settings: 
Questionnaire Feedback 
Method 
A questionnaire was used to gather information from services to provide a more robust 
estimation on the scale of the impact of NPS for secure mental health settings. This 
questionnaire aims to gather information on the prevalence of people using NPS and related 
clinical symptoms alongside the wider impact of NPS in care settings to understand what 
support might be useful for secure mental health settings. 
An online questionnaire was circulated to secure mental health units between 6th January and 
21st February 2017. A copy of the questionnaire is included following the conclusions of this 
appendix.  
Responses to the completed questionnaires were collated. Descriptive analysis was 
undertaken for the quantitative responses and thematic analysis was undertaken for the 
responses to the qualitative questions.  
 
14 
 
 
Results  
Responses by Setting 
66 responses to the questionnaire were received in total. These comprised of ; 37 from a low 
secure setting, 15 from a medium secure setting, 5 from a forensic unit and 9 from a CAMHS 
setting. 0 responses were received from high secure mental health settings. The responses 
represented a total of 1781 current patients.  
Prevalence of NPS Use  
11 of the 66 units that responded to the questionnaire reported one or more service users 
currently using NPS. However prevalence within these units was low with a total of 20 patients 
across all units reported to be current users. The prevalence by unit type is shown in Table 1 
below:  
 
 Low 
Secure 
Medium 
Secure 
Forensic 
Unit 
CAMHS  Total 
Total patients 807 666 192 116 1781 
Number recorded as 
current NPS users  
10 2 4 4 20 
Current NPS Prevalence 
(%) 
1.24 0.3 2.08 3.45 1.12 
Table 1: Current recorded prevalence of NPS use by unit type 
 
However, the number of current patients recording as using NPS prior to admission was 
higher. Overall 218 patients (12%) were recorded to be using one or more NPS prior to 
admission to the unit. Table 2 shows the prevalence of NPS use prior to admission by secure 
mental health unit type:  
 
 Low 
Secure 
Medium 
Secure 
Forensic 
Unit 
CAMHS  Total 
Total patients 807 666 192 116 1781 
Number recorded as 
using NPS prior to 
admission 
94 100 11 10 218 
Prevalence of NPS use 
prior to admission (%)  
11.63 15.02 5.73 8.62 12.07 
Table 2: Recorded prevalence of NPS use prior to admission by unit type 
 
In the last 12 months 40 of the 66 units that responded reported that at least one patient had 
been admitted with NPS as a causal or contributory factor for admission. This equated to 105 
patients in total; 37 for low secure, 52 for medium secure, 10 for forensic and 6 for CAMHS 
settings.  
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Sources of admission for those using NPS  
Admission routes for those using NPS were reported by unit. The most common source of 
admission for those currently using NPS was from another mental health unit (33 patients) 
followed by a prison setting (24 patients), a community setting (13 patients) and another 
hospital setting (4 patients).  
 
Types of Substance Used  
The types of NPS used were reported by unit. In total 46 units reported some use of synthetic 
cannabinoids (SC), 12 reported some use of depressants, 31 reported some use of stimulants 
and 11 reported some use of hallucinogens. Table 3 below shows the breakdown of reported 
NPS used by unit:  
 
 NPS type 
Unit type Synthetic 
Cannabinoid 
Depressant Stimulant Hallucinogen 
Low Secure 26 4 16 4 
Medium 
Secure 10 3 8 5 
Forensic 
Unit 4 3 3 0 
CAMHS 6 2 4 2 
Total 46 12 31 11 
Table 3: Recorded NPS usage by unit type  
 
The most common type of NPS used was reported by unit. Figure 1 below shows the most 
prevalent NPS used reported by unit type. For all units synthetic cannabinoids were reported 
as the most prevalent NPS in use. 
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Figure 1: Chart to show the most commonly reported NPS used by 
unit type  
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Depressant
Stimulant
Hallucinogen
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In terms of specific NPS used the most commonly recorded NPS used across the units was 
Spice (a synthetic cannabinoid) followed by; Black Mamba (a synthetic cannabinoid), Ketamine 
(a depressant) and magic mushrooms (hallucinogens). Other specifically named substances 
included: Clockwork Orange and Cotton Candy Carnage (synthetic cannabinoids);  
Barry White, Rave, GoGaine, Blow, Mcat, Methamphetamine, Meow Meow, MDMA 
(stimulants) and LSD (a hallucinogen).  
 
Poly-substance use  
 
Of those recorded to be using NPS in a secure mental health setting 66.4% were also reported 
as using another illicit substance. Prevalence of dual use was highest in a CAMHS setting 
(78.6%) followed by medium secure settings (72.5%), forensic units (66.7%) and low secure 
settings (58.7%). Cannabis was the most commonly reported substance used alongside NPS 
followed by cocaine, amphetamines, heroin, crack and other unspecified substances.  
 
Clinically relevant symptoms and incidents  
Physical Symptoms Linked to NPS Use  
Cardiovascular symptoms were the most frequently reported physical symptom to be 
associated with NPS use, followed by reduced levels of consciousness, dizziness, vomiting 
and neuro-muscular symptoms. Figure 2 below shows the frequency of physical symptoms 
associated with NPS use reported in secure mental health settings. 
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Psychological Symptoms Linked to NPS Use 
 
Psychosis was the most frequently reported psychological symptom to be associated with NPS 
use, followed by aggression, anger, paranoia, anxiety and hallucinations. Figure 3 below 
shows the frequency of psychological symptoms associated with NPS use reported in secure 
mental health settings.  
 
 
 
 
Acute Response to NPS Use 
14 of the 66 secure mental health units reported the need for urgent clinical care related to 
NPS use in the last 12 months, this related to a total of 52 incidents. For the units that provided 
information on the type of response required reports were given on the need for ambulance 
attendances and acute hospital admissions to manage physical symptoms such as loss of 
consciousness and respiratory symptoms related to NPS use.  
 
 
 
 
 
 
 
Additional feedback for units reporting acute incidents related to NPS were linked to 
exacerbations of psychological conditions including acute management of anger and 
aggression on the unit.  
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Figure 3: Chart to show frequency of psychological symptoms reported by secure 
mental health settings 
“One young person reacted badly to the substance she started convulsing and her lips started turning 
blue. The second young person had an increase in paranoia, an increased pulse rate and feelings of 
tightness in his chest. First Aid was given and paramedics were called. The young people were then 
placed on 15 minute observations on the advice of the ambulance crew.” 
“Patient collapsed in bathroom and hit head requiring assessment in hospital – twice” 
 
“Service users have collapsed and become unconscious on many occasions requiring physical 
observations and emergency intervention.” 
“The unit has used open seclusion beds to manage and monitor service users under the influence of 
NPS. The unit has used seclusion to manage violent, threatening and aggressive behaviour relating to 
NPS use on the unit and related deterioration of mental health.” 
“Signs of relapse of acute mental illness, agitation and aggression towards staff also paranoid 
thoughts.” 
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Withdrawal symptoms associated with NPS use  
8 of the 66 units reported that one or more patients experienced withdrawal symptoms from 
NPS in the last 12 months. Physical symptoms that were associated with NPS withdrawal 
included: nausea, vomiting, sweating and tremors. Psychological symptoms that were 
associated with NPS withdrawal included: aggression, insomnia, irritability, anxiety, psychosis, 
paranoia and hallucinations.  
 
Wider Impact of NPS on the Unit 
Impact on the culture between patients on the unit  
Units reported a number of different areas where they felt the use of NPS may have had an 
impact on culture within the mental health setting. These included:  
 Perceived impact on allocation of staffing resources  
 
 
 
 
 Impact on leave from the unit  
 
 
 
 Trading and Exploitation  
 
 
 
 
 Perception of the risks associated with NPS use  
 
 
 
 
 The perception of those using NPS by non-users within the unit. 
 
 
 
“Those who don't use become angry and frustrated with those who use due to the disruption on the 
ward and that more nursing time is taken up by those who use.” 
“Other patients being verbally abusive to the user as they were taking all the staff time, either being 
restrained in the bedroom or cleaned as they had soiled it.” 
“Pressure on patients with unescorted leave to import drugs on behalf of others without leave.” 
“There appeared to be an increase in tension between peers, this was the result of the intense 
observations required after patients had returned from AWOL under the influence of illegal 
substances, which had a detrimental effect on other patients accessing their leave and engaging in 
their therapeutic program.” 
 
“We have experienced dealing and supply issues among service users incurring debt and causing 
tension on the unit.” 
“NPS has been brought onto the unit and shared with others, including one patient who was not 
previously a substance abuser. There can be a culture of intimidation to obtain money from 
vulnerable patients to obtain NPS.” 
“There is concern regards patients who may have not previously used illicit substances in the 
community and using these due to the label of 'legal high' which is confusing for people.” 
“These substances are often (and mistakenly) believed to be harmless, which again may encourage 
some of the patients to use them instead of other drugs.” 
 
 
 
 
“Young people became very wary of the young person who brought the drugs on to the unit; the 
young person wanted to discharge herself and did not want any assistance with her drug use.” 
“There have been issues of grassing and suspicion between patients.” 
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• Violence within the unit and impacts on security 
 
 
 
 
 
 
 
 Impact on ability to test for NPS on the culture 
 
 
 
 
 
• However a number of units reported no current impact on culture due to NPS. This was 
reported to be due to either NPS use not being prevalent in the unit or mitigating action taken 
by the unit such as education on the impact of NPS.  
 
 
 
 
 
Other challenges that NPS use may have presented on the unit 
 Respondents reported a number of other challenges that NPS have presented to secure 
mental health units. The key themes for these challenges included:  
• Increased incidents of violence and aggression caused by NPS use. 
 
 
 
 
 
 Issues of bullying and safeguarding for vulnerable patients.  
 
 
 
 
 
• Security Issues  
 
 
Security has found hidden cannabis in the grounds. Patients have in the past shared their 
cannabis with other patients. 
 
“Patients have had to be moved due to risk and subverting security. Tense atmosphere linked to 
unpredictability of behaviour - impacting on staff and service users”  
“Retrospective review of care reveals more number of violent incidents in the ward and increased 
disengagement following use of psychoactive substances.”  
“The relative difficulty in testing ie longer result times, undermines monitoring procedures.” 
“Many patients appear to believe that urine tests cannot detect any of the NPS (despite we actually 
have dedicated tests in the unit), which potentially increases the risks of some of them using such 
drugs.” 
“This has not been a prevalent issue this year due to education around the impact of NPS” 
“NPS don't seem to have affected the culture of the unit.” 
 
 
“Its use increases levels of violence/intimidation towards staff.” 
“Physical assaultive behaviour, verbal challenges towards staff and other patients” 
 
 
“Intimidation of more vulnerable residents to import substances.” 
“There has been an increase in bullying type behaviours where ward based patients tend to 
pressurize patients with leave by asking them to bring in contraband items”. 
 
 
“Breaches of security (including use of drones).” 
“We have in the past had an issue with young people asking friends to bring in NPS and also making 
arrangements with a dealer to deliver NPS in th unds.” 
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• Concerns related to the difficulty in identifying those using NPS.  
 
 
 
 
 
 
 
• Issues related to debt and financial exploitation  
 
 
 
 
 
 
• Exacerbation of mental health conditions and interference with treatment  
 
 
 
 
 
• Impacts on staffing resources on the units 
 
 
 
 
 
• Concerns about the impact of NPS on the physical health of service users  
 
 
 
 
 
 
  
Management of people using NPS 
 
22% of respondents reported that they have a protocol in place for the treatment of people 
using NPS. The proportion of units with a protocol in place varied by unit type, protocols were 
in place for; 25% of low secure, 31% of medium secure, 25% of forensic and 13% of CAMHS 
units. 
 
“Difficulties with testing make risk management difficult as residents even when clearly clinically effected 
deny use.” 
“Inability to detect NPS using standard drug services even sophisticated ones. Restriction of leave when 
NPS use/trading has been established but also when it has been suspected, leading to patients declaring 
unfair treatment.” 
 
 
“Patients with leave periods have in the past been known to charge extortionate amounts of money in 
order to bring in illicit substances.” 
“The young person in question denied that she was in any drug debts but did admit that she has slept 
with older men in order to obtain drugs.” 
“Interference of psychoeducational therapies.” 
“At times prescribed medication may have needed to be withheld due to the unknown effects of the 
substance they had taken.” 
“Increased staffing required due to 1:1 interventions to monitor physical health, NPS related 
seclusions and dealing of substances on the unit.” 
“Patients would present in a challenging unpredictable manner often requiring higher levels of staff 
support.” 
“Separated smoking areas and smoke times, removal of tobacco and NRT management to manage 
and prevent unconsciousness and risk to life.” 
“There is also the risk of seizures/other physical health complications from NPS this has previously 
impacted on our ability to make the best use of resources as we have had to undertake high risk 
escorts to acute hospitals for physical health assessment.” 
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Regarding the specific aspects of NPS management overall 44% of units reported they had 
treatment plans in place for people using NPS and 28% of units reported that they had plans in 
place to manage the withdrawal of people using NPS.  
 
Table 4 below shows the point at which NPS use is reported as being recorded by secure 
mental health unit type.  
Table 4: Methods for recording NPS use by unit type  
 
 
Table 5 below shows the treatment that is currently available for people identified as using NPS by unit type.  
Table 5: Treatment offered for the management of people using NPS by unit type.  
 
  
 
 
 
 
 
 
Additional information and support identified by secure mental health settings in relation to 
NPS.  
The following themes were identified by respondents as areas where additional support may 
be required regarding the management of people using NPS.  
 Information and training for staff  
 
 
 
 
 
 
 
 
Unit type On admission 
to the unit  
During clinical 
review 
Following ad-hoc 
discussions with 
patients 
On suspicion 
of symptoms 
Not routinely 
recorded 
Low secure 27 23 19 27 1 
Medium secure 13 10 11 10 0 
Forensic unit 3 2 4 4 0 
CAMHS 9 6 4 3 0 
Total 52 41 38 44 1 
 
 
Unit type 
Psychosocial 
interventions  
Symptom 
focussed care 
Clinical 
interventions  
Reduction 
support 
Relapse 
prevention  
Low secure 22 12 15 7 22 
Medium secure 9 6 7 4 8 
Forensic unit 4 3 2 1 3 
CAMHS 3 2 3 0 3 
Total 38 23 27 12 36 
“Update on NPS. All clinical personnel should be aware of this problem” 
“Greater education about the different forms of NPS and the symptoms to look out for. As a unit that 
has experienced fairly minimal problems with NPS over the last 12 months, some form of further 
training would be useful for members of staff. For instance, regional training on - prevalence, 
symptoms, signs, immediate management, and a collaborative approach to prevention.” 
“Advice relating to medical management of specific NPS, in particular with reference to acute 
symptomatology following use, and management of withdrawal.” 
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 Information for service users  
 
 
  
 Support with identification of those using NPS specifically related to options for screening  
 
 Identification of people using NPS and testing. 
 
 
 
 
 
 
 Further information on specific substances  
 
 
 
 
 
 
• National guidance to support the management of NPS in secure mental health settings. 
 
 
 
 
 
 
 
 The opportunity to share good practice and learning between mental health units and 
other agencies. 
 
 
 
 
 
 
 
In addition to the key themes identified by the respondents to the questionnaires further 
comments were raised regarding:  
 Perceived reduction in NPS use since the introduction of the Substance Act.  
 Legal avenues for responding to NPS related incidents 
 Suggestions for a government strategy to address the distribution of NPS.  
 Further research into the risks associated with NPS use 
“Easy read patient information for patients with learning disability” 
“Information on possible clinical interventions and leaflets for patients (and staff) on effects and 
dangers associated with NPS use.” 
 
“Ability to test patient's urine/blood locally but also cost effectively.” 
“Whether there are screening kits available to act as a deterrent.” 
“Accurate, rapid, comprehensive drug screening to make it easier to identify patients taking NPS.” 
 
“Guidance as to what we should be providing.” 
“Medical guide to emergency treatment of symptoms of NPS use/overdose” 
“Any new guidelines for the management of NPS abuse as distinct from other illicit substance abuse.” 
“Names and types of any products new to the market to enable monitoring by staff” 
“Hard to keep up with compounds, up to date information would be welcome.” 
“A regular update on what substances are currently in circulation and any changes or new 
substances.” 
“Examplars of policies, protocols, care plans that address NPS use” 
“Would be good to know how other areas are managing NPS use within their services - issues, ways 
of identifying use- Patients tricks for hiding, obtaining NPS on units- Best treatment options 
identified.” 
“Networking with other specialist agencies that have more information regarding NPS.” 
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Discussion  
Overall recorded prevalence of NPS use within secure mental health settings remains 
relatively low, but reported prevalence of use prior to admission is much higher. The majority of 
units who responded to the questionnaire (44/66) reported that they had a least one patient in 
the last 12 months with an admission that was related to NPS use. This demonstrates that 
NPS use is an issue relevant to secure mental health settings and one that could be having an 
impact on the overall number of people admitted to the units.  
With regards to the type of substance used in secure mental health settings, synthetic 
cannabinoids were the most commonly reported NPS followed by stimulants. Reported use of 
depressants and hallucinogens were proportionally lower. Higher reported use of synthetic 
cannabinoids was reported across all types of secure mental health setting. It is important to 
note that prevalence of NPS use of alongside other illicit substances was high across all types 
of secure mental health setting, with two thirds of NPS users reporting as using other illicit 
substances.  
For symptoms attributed to NPS use psychological symptoms were more frequently reported 
than physical symptoms. Over half of units reported patients using NPS had experienced drug 
induced psychosis and nearly half of units reported patients had experienced anger, 
aggression and paranoia as a result of NPS use.  
One fifth of units reported the need for at least one acute response in relation to NPS in the 
last 12 months. The majority of these responses were related to acute physical problems but 
responses were also required for exacerbations of psychological conditions. Physical and 
psychological problems associated with NPS withdrawal were reported by 12% of units.  
In terms of impact of NPS use on the culture of the unit the most common issues reported 
related to: impact on staffing resources, trading and exploitation, violence and impact on 
security, impact on leave from the unit, tensions between those who use NPS and those who 
don’t, and perception of risk associated with NPS use. Other challenges reported by the units 
in relation to NPS use included; violence and aggression, safeguarding, security, debt, issues 
related to testing and identifying those using NPS, interference with treatment and impact on 
the physical health of users.  
Regarding the management of NPS use only around a fifth of units reported having a protocol 
in place for the treatment of people using NPS, however over two fifths reporting having NPS 
treatment plans in place.  
The main areas where secure mental health units requested further support regarding the 
management of NPS use were; staff training, service user information, testing for NPS, 
information on specific substances, additional national guidance and opportunities to share 
learning with other units.  
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Conclusions 
The feedback from the questionnaire has confirmed that NPS use is an issue that affects 
secure mental health units, both with regards to current use within the units and as a potential 
contributing factor for admission to the units. Synthetic cannabinoids are the most commonly 
used type of NPS but other substances are also in use. It is important to note that the majority 
of NPS users in mental health settings also use other illicit substances.  
Psychological and physical symptoms associated with NPS use have an impact on the care of 
service users, in particular in relation to staffing resources and the management of acute 
incidents. Units have reported challenges in relation to being able to identify those using NPS 
and tensions between users and non-users within the unit. Issues have also been identified in 
relation to financial exploitation, allocation of leave, interference with treatment and 
safeguarding of vulnerable patients.  
New Psychoactive Substances Questionnaire 
1. Setting  
1.1 Name of the setting  
 
1.2 Name of the person completing the 
questionnaire  
 
1.3 Date questionnaire 
completed  
 / / 1.4 Number of beds in the unit  
1.5 Type of setting  CAMHS  High Secure Medium Secure   Low secure Forensic unit  
2. Prevalence  
2.1 How many patients are currently on the unit?  
2.2 How many people currently on the unit are recorded to be currently using NPS?  
2.3 How many people currently on the unit were recorded to be using NPS prior to admission?  
2.4 In the last 12 months how many people admitted to the unit had NPS recorded as a causal or 
contributory factor for admission?  
 
2.5 Please specify the sources of admission for those patients using NPS (please tick. More than one option can be 
chosen) 
Another mental health unit Prison  Community  Other (please specify) 
2.6 What types of NPS are used? (Please tick. More than one option can be chosen) 
25 
 
 
Synthetic Cannabinoids  
eg Spice, Black Mamba 
Depressants  
e.g GHB, GBL,  
 
Ketamine 
Stimulants  
eg Mcat, Meow- 
 
Meow, MDMA 
Hallucinogens  
eg LSD, Magic  
 
Mushrooms, 
 Other 
2.7 Which is the most common type of NPS used? (please specify) 
 
2.8 Of those using NPS what number of patients are recorded as using other illegal substances?   
2.8a. Please specify the other illegal substances used:  
3. Clinically relevant symptoms and incidents 
3.1 Please indicate any clinically relevant physical symptoms that have been recorded as a result of NPS:  
Cardiovascular symptoms  Renal symptoms Gastro-intestinal symptoms Convulsions  
Neuromuscular  
symptoms 
Numbness /  
tingling 
Reduced levels of 
consciousness 
Hyperglycaemia/ 
hypoglycaemia  
Respiratory symptoms Dizziness  Tremor  Vomiting 
Other (please specify)  
3.2 Please indicate any clinically relevant psychological symptoms that have been recorded as a result of NPS: 
Anxiety  Memory loss  Psychosis Depression Anger/Aggression  
Suicidal thoughts  Confusion Panic attacks  Paranoia Hallucinations 
Other (please specify) 
 
3.3 Has the unit had any emergency incidents in the last 12 months related to NPS where 
additional urgent clinical care was required? (please tick) 
Yes No  
If yes please specify: 
a) The number of incidents: 
 
b) The nature of incidents and the response that was required eg acute clinical care 
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3.4 In the last 12 months has anyone on the unit experienced any physical or psychological 
symptoms as a result of withdrawal from synthetic cannabinoids?  
Yes No  
If yes, specify; symptoms experienced, severity of symptoms and frequency.  
 
 
 
4. Wider impact of NPS on the unit  
4.1  Please detail any impact you feel that the use of NPS might have had on the culture between patients within 
your setting:  
 
 
 
 
4.2  Please detail any other challenges that the use of NPS may have presented in relation to providing care in the 
unit (eg assaults, debt, bullying) 
 
 
 
5. Management of people using NPS 
5.1 Does the unit have a protocol for the treatment of people using NPS? (please tick) Yes No  
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Thank you for completing the questionnaire. 
Please return the questionnaire to sarahsmith30@nhs.net by 21/02/2017 
 
 
 
 
 
5.2 At what point is NPS use recorded? (please tick, more than one option may be ticked) 
On admission to the unit During clinical review  Use not routinely recorded  Other 
 
 
Following ad-hoc discussions with patients  
 
 
On suspicion of symptoms  
 
5.3 Are treatment plans in place for people using NPS? (please tick) 
 
Yes No  
5.4 Does the unit have plans in place to manage withdrawal of people using NPS? (please tick) Yes No  
5.5 What treatment is currently available for people identified as using NPS? (please tick)  
Psychosocial interventions  Symptom-focussed care  Clinical interventions  Reduction support 
Relapse prevention Other (please specify) 
  
5.5 What additional information would the unit find useful to assist with the management of people using NPS? 
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Appendix 3: An Evidence Review of New 
Psychoactive Substances in Secure Mental 
Health Settings  
First published:  July 2017 
Updated:  Not applicable 
Prepared by:  Sarah Smith on behalf of NHS England Specialised Commissioning 
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1. Introduction  
New Psychoactive Substances (NPS) are a group of illicit substances which are increasing in use in the 
UK and across Europe. This rise, coupled with links to significant physical and psychological 
comorbidity, has led to NPS being a growing concern for public services in recent years 1,2.  
Previously referred to as “legal highs” these NPS are now controlled under the Misuse of Drugs Act 
2016 2. They are substances that often mimic other controlled substances through stimulation or 
depression of the central nervous system 1. NPS are categorised into four main subgroups; synthetic 
cannabinoids, stimulants, depressants and hallucinogens. In practice there are many types of NPS 
available which are often distributed in ways to evade detection and legal prohibition such as being 
marketed as bath salts, research chemicals or plant food. Due to the vast number of NPS in circulation 
and the different methods for circulation including via the internet it is often difficult for healthcare 
professionals to keep up to date with the specific types of substances in use. This, in addition to 
perceptions around legality of the substances poses a significant problem for health and justice 
systems 1.  
In 2015/16 2,042 individuals presented to substance misuse treatment services for NPS in England, 
whilst this was a 77% increase on the previous year it still only represented 1.5% of all presentations 3. 
The proportion of young people accessing the same services for NPS in 2015/16 was higher at 6% this 
again was an increase from the previous year 4.  
In secure settings the proportion of those accessing services for treatment for NPS use was higher than 
in the community with 6% of adults and 8% of young people in treatment reporting NPS as a problem 
substance 5. As with all the figures for those accessing treatment this only represents the proportion of 
those using the substances who are seeking treatment; the prevalence of use is likely to be much 
higher.  
The negative physical and psychological effects of NPS have been widely documented and include 
acute cardiovascular and respiratory symptoms, altered levels of consciousness, agitation, psychosis, 
hallucinations and in some cases death 6. Due to the acute nature of the NPS related reactions people 
are most likely to attend acute settings such as emergency departments. However NPS use may also 
present longer term health problems such as renal damage and health issues associated with 
dependence where users may present at primary care or mental health settings 1, 2, 6. 
Aims and Objectives  
This review aims to summarise information on the impact NPS use is having on secure mental health 
settings; both in terms of the scale of the problem (prevalence of NPS use) and the clinical and 
managerial impact this has on services.  
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The review also aims to summarise effective interventions that aim to reduce the scale and the impact 
of NPS use in mental health settings. This may include interventions that can be implemented in clinical 
practice in addition to larger scale policy interventions.  
Evidence review questions:  
Primary research question; 
 What is the impact of NPS use on secure mental health settings and the people accessing those 
settings? 
 
Supplementary research questions:  
 Is there a causal link between NPS and mental health conditions? 
 Has the use of NPS caused an increased number of people being admitted to secure 
mental health settings?  
 What is the most effective way of treating people in secure mental health settings who are 
users of NPS?  
 
 
2. Summary of results 
The 24 papers identified for inclusion in this evidence review highlight a number of themes related to 
the impact on NPS in secure mental health services.  
The results from the review indicate that NPS can induce psychiatric symptoms in those with no prior 
mental health diagnosis and can exacerbate symptoms in those with existing serious mental illness. 
This may translate to an impact on admissions and care in secure mental health settings. The findings 
from the review recommend that clinicians are aware of the potential for NPS to induce mental health 
symptoms and how this can be diagnosed and treated. The findings also indicate that patients should 
be educated about the psychological and other harms of using NPS and a culture of self-reporting of 
NPS use should be fostered in order to assist treatment.  
This evidence review has highlighted that limited evidence available in this field and further research 
would be recommended to better address the research question. 
 
3. Method 
A systematic literature search of peer reviewed publications. As the subject matter is relatively new 
the search terms were purposefully broad in order to generate sufficient papers for review. Search 
terms with derivatives of New Psychoactive Substances and mental health were used.  
The search strategy for this evidence review is detailed in Section 9 of this document.  
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The following databases were searched: PubMed, The Cochrane Library, Elsevier, and Embase. 
The title and abstract fields were included in the search. No restrictions were made on date or 
country of publication.  
 
Once papers were identified through the search strategy the titles were screened for relevance, 
duplicate papers and those not meeting the inclusion criteria were excluded. The abstracts were 
then screened and those not meeting the inclusion criteria at this stage were excluded. Finally full 
text reviews were completed and any remaining papers not meeting the inclusion criteria were 
excluded. The remaining papers were included within the evidence review.  
 
Thematic analysis was conducted for the papers included in the review to identify the key areas for 
discussion. The outcomes of the included papers were also considered against the primary and 
supplementary research questions. 
 
4. Results 
 
Literature Review Results 
 
Through the literature search 19 papers were identified for inclusion in this evidence review. 2 
additional papers were identified through feedback from other professionals working in the field. 3 
additional papers were identified through Public Health England’s internal peer review process. 
Due to the emerging nature of the subject matter the volume of relevant published literature was 
low and papers identified were relatively new (2010 - 2017). The majority of the papers included 
were individual case reports (n = 7), followed by review papers (n = 5), clinical audits (n = 3), case 
reports (more than one case) (n=2), retrospective audits of case notes (n = 2), systematic reviews 
(n=2), qualitative studies (n= 1), surveys (n=1), and epidemiological studies (n=1). 
 
Where stated in the included studies the age profile of the participants tended to be younger adults, 
ranging from 20 – 30 years in the individual case reports to mean ages of between 15.4 years and 
40 years in the studies with larger sample sizes. Where sex was reported in the studies the 
proportion of males was higher than the proportion of females.  
 
Regarding the types of NPS considered within the included studies 5 papers considered multiple 
NPS types and did not limit the study to a specific substance or group of substances, 12 papers 
considered synthetic cannabinoids, 2 considered depressants (ketamine like substance and 
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Benzylglycinamide), 4 papers considered stimulants (mephadrone and ethylphenidate) and no 
papers solely considered hallucinogenic substances. 1 paper did not specify the NPS under study.  
 
Where the settings for the studies were stated (n = 15) the majority related to inpatient mental 
health settings (n=9), followed by emergency department attendances (n= 6), community settings 
(n = 2) and a prison setting (n = 1). 
 
With regards to the mental health status of subjects within the included studies 10 reported NPS 
induced symptoms on subjects with no pre-existing mental health conditions; 4 reported on NPS 
exacerbating existing mental health conditions and 10 papers reported on both the onset of 
symptoms in previously undiagnosed patients and the exacerbations of existing conditions.  
 
Summary of results relating to research questions 
 
What impact does NPS use have on secure mental health settings?  
The papers included within this evidence review were able to partly address this research question. 
The included papers were able to indicate the impact NPS may have on inducing psychological 
symptoms and exacerbating existing symptoms 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 18, 20, 21, 23, 24, 25, 27, 28, 29, 30. The 
papers also give an indication of potential physical comorbidities that may affect those using NPS 
in secure mental health settings 13, 23, 24.  
Another area the included studies may add insight is related to the emergency hospital care those 
with NPS induced acute psychological symptoms may receive prior to admission to a secure 
mental health unit 8, 10, 11, 12, 13, 17, 18, 20. This review also considers evidence on treatment options for 
the management of acute psychiatric symptoms associated with NPS use 10, 14, 26.  
 
Supplementary Research Questions  
 
Is there a causal link between NPS and mental health conditions? 
The studies identified in this review appear to indicate a link between certain NPS and acute onset 
of psychological illness. Symptoms including; psychosis, anxiety, aggression, agitation, catatonia 
and hallucinations were reported as being attributable to NPS within subjects with no prior mental 
health diagnosis 7, 8, 9,10, 11, 12, 13, 14, 18, 20, 21, 23, 25, 27. Further research may be needed to determine the 
longer term mental health effects of NPS use and whether NPS use could lead to the development 
of chronic mental health conditions.  
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Has the use of NPS caused an increased number of people being admitted to secure mental 
health settings?  
A number of the papers included in this review reported emergency hospital admissions to 
psychiatric wards following acute onset of psychological symptoms following NPS use 8, 9, 14, 17. 
However due to the small sample sizes in the included papers, this limits the applicability in 
practice. The included studies do not provide an indication of the population wide impact on 
admissions to secure mental health units where NPS use was a causal or attributable factor.  
 
What is the most effective way of treating people with mental health conditions who are 
users of NPS?  
The evidence in the included studies was limited with regards to mechanisms for the effective 
management of people using NPS in secure mental health settings. Recommendations for 
pharmacological support were considered in three papers 14, 22, 26 and methods for supportive 
treatment were considered in two papers 22, 26. Overall the papers included within this study did not 
adequately address this question. This is a question that would benefit from further primary 
research specifically in relation to non-pharmacological methods for management and whether this 
differs from treatment for other illicit substances.  
 
Thematic Analysis: 
To consider the key themes covered in this review analysis was undertaken detailing themes 
discussed in two or more included research papers. The key themes that arose from the review are 
detailed in figure 1 below.  
 
5. Discussion 
5.1 Principal Findings of the Evidence Review  
Papers identified through this evidence review highlight a number of themes that indicate the impact 
NPS use may have on secure mental health settings. The findings of this review allow the impact to be 
considered in terms of: NPS inducing mental health conditions, exacerbation of psychiatric symptoms, 
the emergency response to those presenting with NPS induced mental health conditions, the impact of 
NPS on the management of secure mental health service users, pharmacological and supportive 
treatment for NPS use, the impact of other substances in addition to NPS and policy initiatives and the 
impact on NPS induced mental health.  
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NPS induced mental health conditions  
NPS use was cited in a number of studies as being a causal factor for inducing psychosis in addition to 
other mental health symptoms including; agitation, insomnia, catatonia, anxiety, aggression, 
hallucinations and suicidal ideation. Generally these symptoms were reported through clinical 
presentation in an acute setting combined with a patient reported history of NPS use. In three studies 
the biomechanical mechanisms for the acute psychotic response to NPS was also identified which 
supports evidence indicating that NPS use can act as a causal factor for mental health symptoms.  
The NPS induced psychiatric symptoms reported were generally acute symptoms for those with no pre-
existing mental health condition. In some cases these NPS induced symptoms were reported to lead to 
wider issues such as self-mutilation and criminal behaviour.  
Admission to secure psychiatric care was required for the ongoing management of symptoms in some 
cases with NPS induced mental health conditions. This may indicate a potential impact on future 
activity, both in terms of volumes of people requiring mental health admissions and the type of care that 
would be required. However due to the numbers of available studies being low and the sample sizes in 
the included studies being relatively small, more research is required to better understand the 
population level impact of NPS induced mental health conditions on admissions to secure mental health 
settings.  
The acute response to NPS induced psychiatric symptoms 
The papers included in this study indicated that the emergency department is a likely route of 
presentation for those with NPS induced psychiatric symptoms. This has implications for those working 
emergency department both in terms of diagnosing and treating those with mental health symptoms 
which may be induced by NPS.  
Studies included in this review recommend that emergency department staff should be aware of the 
potential of NPS to induce psychiatric symptoms and to understand which psychiatric symptoms might 
be more commonly associated with different groups of NPS.  
Clinicians should understand that different classifications of NPS require may present with different 
symptoms and require different mechanisms for assessment and management. 
This is a particularly important issue for NPS use compared to other illicit substances as, due to the 
emerging nature of the substances, many may not appear on drug screening tests. Therefore the 
studies recommend that clinicians should be aware that NPS use may be a causal factor for acute 
mental health presentations where people presenting appear to be under the influence of an illicit 
substance but present with a negative drug screen.  
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The included studies recommend that emergency department clinicians should be educated about the 
treatment options available for NPS induced psychosis including supportive and pharmacological 
treatment.  
Emergency department staff should be conscious of the potential of outbreaks of NPS induced 
psychosis where multiple patients attend with similar symptoms, reporting using the same NPS.  
 
The impact of NPS on the management of those in secure mental health settings  
The included studies also report that NPS can exacerbate the psychiatric symptoms of those with 
existing serious mental health conditions. Therefore healthcare professionals working in mental health 
settings should be aware of the psychiatric symptoms associated with NPS use in units where use is 
confirmed or suspected. These symptoms may include increased psychosis, anger, aggression and 
violence which may pose a challenge for the management of patients in secure mental health settings. 
NPS use may also be associated with a longer length of inpatient stay. Further research would be 
required to determine if this is an issue that is perceived in practice. Staff should also be aware of the 
potential for psychiatric effects from the withdrawal of NPS.  
Due to the challenges with testing for specific substances mental health staff should encourage a 
culture of self-reporting of NPS use in secure mental health settings to ensure management is 
appropriate.  
Mental health professionals should also be aware of the physical symptoms associated with NPS use 
as this may impact on those using NPS who are under their care. Staff should be made aware of both 
acute physical symptoms such as loss of consciousness in addition to longer term physical health 
problems associated with use such as bladder complications.  
Mental health professionals should be aware of the pharmacological and supportive treatment options 
for NPS use in those with existing mental health conditions. Due to the limited evidence in this field 
identified by this review further research would be welcomed in this area specifically related to how 
treatment options for NPS use interact with treatment for existing serious mental illness.  
 
Policy initiatives for NPS that impact on mental health  
One paper identified a link between the decreased retail availability of NPS and decreased 
presentations of those with NPS related mental health symptoms. This suggests that if policy initiatives 
and legislation were able to limit NPS supply this may have an impact on reducing NPS related activity 
in mental health services.  
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Another included paper discussed the potential use of social media surveillance related to NPS terms 
as a potential early warning system for health professionals. This may be an area that could be 
explored further to give mental health settings an indication of potential increases in activity linked to 
NPS induced psychiatric symptoms.  
Another area highlighted through the review which may have an impact on secure mental health 
settings was the recommendation to increase public and patient awareness on the health 
consequences of using NPS. Specifically around the mental health impacts of specific substances. 
 
Evidence Review Limitations  
As NPS use and the impact on mental health is a relatively emerging topic,the quantity of available 
evidence was limited. The quality of evidence that was available was also limited to case reports, 
clinical audits and case note audits (n = 13), with only 2 systematic literature reviews meeting the 
search criteria. Therefore the validity of the finding and generalisability in practice is limited. The review 
however was able to identify a number of key themes from the included studies which were relevant to 
the primary research question and recommend further areas where additional research would be 
beneficial.  
 
Recommendations for future research: 
As evidence related the impact of NPS for mental health services is an emerging field additional 
research would be welcomed in a number of areas. Findings from this evidence review have identified 
the following as potential primary research questions:  
 Has the use of NPS lead to an increase in mental health prevalence at a population level? 
 Does the use of NPS lead to the development of chronic mental illness?  
 Have NPS induced psychiatric symptoms led to an increase in activity in secure mental health 
settings?  
 What is the prevalence of NPS use in secure mental health settings?  
 What are the recommended treatment options for NPS use in secure mental health settings? (to 
include supportive and pharmacological approaches to treatment) 
What impact does the use of NPS have on clinical management in secure mental health settings? 
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Conclusion  
This evidence review has identified some areas where NPS use may have an impact 
on secure mental health settings both in terms of the potential impact of increased 
mental health prevalence induced by NPS and the impact of NPS use of those under 
secure psychiatric care.  
The review indicated that NPS can induce mental health symptoms which can require 
admission to secure mental health services, and NPS users may require longer 
inpatient stays. It also raises the importance of emergency staff and secure mental 
health staff being aware of the psychiatric symptoms associated with NPS use to 
ensure appropriate diagnosis and treatment.  
At policy level public and patient education on the mental health impacts of NPS is 
recommended to ensure people are aware of the risks of use.  
Further research would be beneficial to determine the impact of NPS use on secure 
mental health settings and to recommend evidence based methods for management of 
associated psychological symptoms.
 7. Evidence Summary Table 
 
Study 
reference 
Study Design 
Population 
characteristics 
New Psychoactive 
Substance(s) 
included  
Setting 
Results relating to 
mental health 
outcomes 
Conclusion 
summary 
Applicability in 
practice 
Stevenson 
and 
Tuddenham 
(2014) 
Individual Case 
report 
Male aged 20-
30 years, n = 1 
3-
methoxyphencyclidine 
(3-MeO-PCP), and 
methylenedioxypyroval
erone (MDPV )An 
analogue of 
methoxetamine, a 
Ketamine like 
substance. 
Community.  
 
No pre-existing 
mental health 
condition.  
NPS induced 
psychosis.  
MDPV can lead to 
NPS induced 
psychosis. 
Symptoms in this 
case lasted 6 weeks. 
The case attempted 
murder whilst under 
the influence of NPS.  
NPS use can induce 
psychosis.  
There may be criminal 
implications for actions 
taken by those under 
the influence of NPS.  
Anderson et 
al (2015) 
Individual Case 
report 
Male aged 30-
39 years, n = 1 
‘El blanco’, reported to 
contain ethylphenidate 
and benzocaine 
Psychiatric 
inpatient 
setting 
NPS incduced 
relapse of paranoid 
schizophrenia  
NPS use can be a 
precipitant for 
relapse among 
patients with 
schizophrenia 
NPS use should be 
considered a possible 
cause of psychiatric 
symptomology 
Caloroa et al 
(2016) 
Individual Case 
report 
24 year old 
female, n = 1 
Benzylglycinamide 
(multi-substance use 
with opiods, cocaine 
and synthetic 
cannabinoids). 
Emergency 
admission to a 
psychiatric 
hospital. 
NPS induced 
psychosis, 
agitation, and 
insomnia. 
Multi-substance use 
including NPS 
contributed to short 
term psychotic 
symptoms.  
Impacts of multi-
substance NPS use 
inducing psychotic 
symptoms. Impacts of 
those using new 
substances 
experimentally.  
DiPetta 
(2016) Individual Case 
report 
 Single patient 
admitted to 
hospital, n = 1 
Specific NPS not 
specified. 
Psychiatric 
hospital 
Synthetic 
psychosis. 
Multi-substance NPS 
use can lead to 
psychosis. 
Multi-substance NPS 
use has implications 
for decline in mental 
health state, increased 
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mental health hospital 
admissions and 
criminal activity. 
Khan et al 
(2016) 
Case report  
 21 year old 
male and 17 
year old male, n 
= 2 
Synthetic 
cannabinoids. 
Hospital 
emergency 
department 
No pre-existing 
mental health 
conditions.  
NPS induced. 
catatonia. 
Catatonia can be 
induced by use of 
synthetic 
cannabinoids (SCs) 
with no existing 
mental health 
conditions. 
Use of SCs may have 
wider psychological 
impacts other than 
psychosis.  
Schwartz et 
al (2016) 
Case report 
 Males and 
females aged 16 
– 30 years, n = 
8 
 
“Crazy Clown” ADB-
PINACA -Synthetic 
cannabinoid. 
Hospital 
emergency 
department 
No pre-existing 
mental health 
conditions.  
NPS induced 
anxiety, 
delirium, psychosis, 
and aggressive 
behaviours. 
Outbreaks of 
psychological 
symptoms 
associated with NPS 
use can be detected 
in emergency 
departments.  
Emergency 
department clinicians 
should be aware of the 
potential of the 
outbreak of cases 
presenting 
psychological 
symptoms for people 
using the same NPS.  
Khullar et al 
(2014) 
Individual case 
report 
20 year old 
male, n = 1 
Synthetic 
Cannabinoids and 
Cathinones. 
Hospital 
emergency 
department  
No prior mental 
health condition. 
NPS induced acute 
psychosis, 
hallucinations and 
severe agitation. 
Use of synthetic 
cannabinoids and 
cathinones can lead 
to patients attending 
emergency 
department settings 
with altered mental 
status including 
acute psychosis  
Emergency 
department clinicians 
should consider 
possible NPS use 
when patients attend 
with psychiatric 
symptoms.  
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Meijer et al 
(2014) 
Individual case 
report 
 26 year old 
male, n = 1 
Black diamond – 
synthetic cannabinoid. 
Hospital 
emergency 
department 
No prior mental 
health condition. 
NPS induced acute 
psychosis, self-
mutilation.  
Use of synthetic 
cannabinoids can 
lead to self-inflicted 
injuries. 
Mental health 
symptoms induced by 
the use of synthetic 
cannabinoids can lead 
to physical injuries.  
Bajaj et al 
(2010) 
Individual Case 
report 
 Young male, n 
= 1 
4-
methylmethcathinone 
(mephedrone). 
Specialist 
mental health 
services  
No prior mental 
health condition  
NPS induced 
psychosis  
Dependant use of 
mephedrone can 
lead to psychosis. 
This case was 
admitted to a 
psychiatric inpatient 
unit and treated with 
medication and 
recovered well.  
Stimulant NPS can 
lead to drug induced 
psychosis. This can be 
treated with 
medication.  
Bassir et al 
(2016) 
Clinical audit 
 Males, mean 
age 40 years, n 
= 594 
Synthetic 
cannabinoids. 
Psychiatric 
inpatient 
setting 
Exacerbation of 
psychosis and 
agitation in patients 
with existing mental 
health conditions.  
When comparing SC 
use with cannabis 
use in a mental 
health inpatient 
setting; psychotic 
presentations and 
agitation are more 
likely to be seen with 
those using SCs.  
Psychiatric co-
morbidity associated 
with SC use varies 
from the symptoms 
associated with 
cannabis use. 
Shalit et al 
(2016) 
Clinical audit 
NPS group n = 
60, mean age 
30.5, 86% male, 
5% married, 
22% employed 
Synthetic 
cannabinoids 
Psychiatric 
hospital 
Multiple mental 
health conditions 
reported 
When comparing 
reported SC use with 
cannabis use in a 
psychiatric inpatient 
setting, SC use was 
associated with 
Patients admitted 
following use of SC 
generally have a 
higher severity of 
psychotic symptoms at 
admission and require 
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Cannabis group 
n = 163, mean 
age 34.7, 80% 
male, 19% 
married, 31% 
employed 
longer 
hospitalizations and 
a more severe 
clinical picture. 
longer hospitalization 
periods. 
Shafi et al 
(2017) 
Clinical audit 
NPS group n = 
58, mean group 
36.2, 74% male 
Non-NPS group 
n = 384, mean 
age 44.9, 52% 
Multiple NPS (91% 
synthetic 
cannabinoids, 7% 
synthetic cathiones) 
Acute mental 
health facility 
Multiple mental 
health conditions 
reported 
NPS use was 
strongly associated 
with violence both 
preadmission and 
during admission. It 
was also associated 
with a longer 
duration of 
admission, 
substance misuse 
disorders and 
psychosis. 
Mental health services 
face an increased risk 
of violence from NPS 
misusers compared to 
non-NPS substance 
misusers. 
Longer length of stay 
in NPS users has 
implications for bed 
utilisation and service 
delivery. 
Kolliakou et 
al (2016) 
Epidemiological 
study 
Median age 30 
years, 84% 
males, n = 468 
Mephedrone. Mental health 
care trust 
Specific mental 
health condition not 
stated.  
Social media data 
can be combined 
with mental health 
records to assist with 
public health 
surveillance related 
to NPS use and 
associated 
psychiatric 
comorbidity.  
Information from social 
media surveillance 
may act as an early 
warning system for 
health practitioners to 
identify potential future 
increases in activity 
associated with NPS 
use.  
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Glue et al 
(2015) 
Retrospective 
audit of case 
notes  
74% males, 
median age 
26.6 – 27.4 
years, n = 62.  
Synthetic 
cannabinoids. 
Emergency 
psychiatric 
service 
Emergency 
attendances related 
to anxiety, 
agitation, 
aggression and 
psychosis. 
The number of the 
number of mental 
health assessments 
related to SC use 
halved following the 
introduction of 
government 
legislation to restrict 
the sale and reduce 
the toxicity of 
psychoactive 
substances.  
Decreasing the retail 
availability of synthetic 
cannabinoids may lead 
to a decrease in 
associated mental 
health harms. 
Besli et al 
(2015) 
Retrospective 
audit of case 
notes  
Mean age 15.4 
years, 94% 
males, n = 16  
Synthetic 
cannabinoids. 
Hospital 
emergency 
department 
No prior mental 
health diagnosis.  
 
NPS induced 
agitation, anxiety, 
hallucinations, 
and perceptual 
changes. 
SC use in 
adolescents can 
induce psychological 
symptoms including; 
agitation, anxiety, 
hallucinations and 
perceptual changes. 
Paediatricians should 
be aware of the 
potential harms of SC 
and how these might 
present in an 
emergency 
department setting.  
Sarpong and 
Jones (2014) 
Review 
 Population 
parameters not 
specified. 
Multiple NPS. Multiple 
settings 
Multiple mental 
health conditions 
reported. 
 
People with mental 
health conditions and 
those who care for 
them should be 
educated about the 
legal and health 
implications of NPS. 
Mechanisms for 
screening would be 
useful to identify 
NPS use in patients 
Education on the 
health and legal risks 
associated with NPS 
use should be 
advocated.  
Mechanisms to readily 
identify NPS induced 
psychosis should be in 
place.  
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presenting with 
psychosis.  
Gurney et al 
(2014) 
Review 
Population 
parameters not 
specified.  
Synthetic 
cannabinoids. 
Emergency 
hospital 
department  
NPS induced 
psychosis, 
confusion, 
unresponsiveness 
and aggression.  
NPS exacerbating 
psychosis in 
patients with 
existing mental 
health conditions.  
SCs have been 
shown to induce 
psychosis and 
exacerbate existing 
mental health 
conditions.  
Mechanisms for 
testing for NPS 
should be developed 
rapidly to keep pace 
with the changing 
nature of SC 
compounds.  
Clinicians should be 
made aware of the 
mental health 
symptoms associated 
with mental health use.  
Options for testing for 
NPS use should be 
explored.  
Fattore 
(2016) 
Review 
 Population 
parameters not 
specified. 
Synthetic 
cannabinoids. 
Multiple 
settings 
NPS induced new 
onset psychosis. 
NPS exacerbating 
psychosis in 
patients with 
existing mental 
health conditions. 
Synthetic 
cannabinoids can 
induce new onset 
psychosis and 
exacerbate existing 
symptoms. This is 
supported by case 
reports and 
biochemical studies.  
Clinical staff should be 
made aware of the link 
between SCs and 
psychosis and other 
mental health 
symptoms.  
The public should also 
be educated about the 
health consequences 
of SCs.  
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Hill and 
Thomas 
(2016) 
Review 
 Population 
parameters not 
specified. 
Multiple NPS. Multiple 
settings 
Multiple mental 
health conditions 
reported. 
Mechanisms for 
clinical assessment 
and management for 
those using different 
classifications of 
NPS. 
Different classifications 
of NPS require may 
present with different 
symptoms and require 
different mechanisms 
for assessment and 
management. 
Lafferty et al 
(2016) 
Survey 
 96% aged 20 – 
49, years, 77% 
males, n = 413. 
Ethylphenidate (a 
stimulant drug 
closely related to 
methylphenidate). 
Community 
harm reduction 
team and 
pharmacy. 
NPS induced 
delusional 
thoughts, 
hallucinations, 
paranoia and 
anxiety. 
Half of those 
injecting NPS 
stimulants reported 
experiencing new 
mental health 
symptoms.  
Injection is a route of 
NPS administration. 
Those who inject NPS 
may also experience 
new mental health 
symptoms.  
Gray et al 
(2016) 
Systematic 
review 
Males aged 20 -
35  
Multiple NPS. Multiple 
settings  
Subjects with 
existing diagnosis 
of schizophrenia or 
delusional/ 
psychotic illness or 
bipolar disorder.  
Exacerbation and 
onset of psychotic 
symptoms and 
behavioural 
changes including 
agitation, 
aggression and 
violence. 
NPS exacerbates 
existing mental 
health symptoms and 
induces new 
symptoms for those 
with existing 
diagnoses of serious 
mental illness (SMI).  
NPS use also causes 
negative physical 
symptoms for those 
with existing SMI. 
Mental health 
professionals should 
be aware of the 
psychiatric and 
physical symptoms 
associated with NPS 
use.  
Health care 
professionals should 
encourage a culture of 
self – reporting of NPS 
use.  
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Castanetoa 
et al (2014) 
Systematic 
review 
 Population 
parameters not 
specified  
Synthetic 
cannabinoids. 
Multiple 
settings  
NPS induced 
anxiety, agitation, 
psychosis, suicidal 
ideation. 
SC use leads to the 
acute onset of 
mental health 
symptoms. The 
acute psychotic 
response to use of 
SC is supported by 
bio-chemical 
mechanisms.  
SCs can lead to acute 
psychiatric symptoms 
which may lead to 
presentation at an 
emergency 
department.  
Weaver et al 
(2015) 
Review 
Population 
parameters not 
specified. 
Multiple NPS. Multiple 
settings 
Multiple mental 
health conditions 
reported. 
Different groups of 
NPS have been 
linked to the onset of 
adverse psychiatric 
effects mainly 
agitation and 
psychosis.  
Withdrawal of some 
groups of NPS may 
also have psychiatric 
impacts.  
Treatment of 
symptoms is mainly 
supportive with some 
pharmacological 
input.  
Clinicians should be 
aware of the 
psychiatric symptoms 
associated with NPS 
use and withdrawal.  
Clinicians should be 
aware of treatment 
options for NPS 
induced psychosis.  
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User Voice 
(2016) 
Qualitative study 
Prison 
population. 
36.7% aged 20-
29 years, n = 
803 
Synthetic 
cannabinoids 
Prison  NPS induced 
psychosis. 
NPS exacerbating 
existing mental 
health conditions. 
Prisoners reported 
mental health 
problems from 
resulting from the 
use of synthetic 
cannabinoids. These 
included self-harm, 
anxiety, depression, 
paranoia and other 
psychotic symptoms. 
Prisoners who use 
synthetic cannabinoids 
self-report 
experiencing mental 
health symptoms.  
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8. Literature Search Terms 
 
Search strategy Indicate all terms to be used in the search 
P – Patients / Population  
Which patients or populations of patients are we interested in? How 
can they be best described? Are there subgroups that need to be 
considered? 
All population groups using New Psychoactive Substances (NPS) with a pre-existing mental health condition 
OR with a diagnosed psychological condition or diagnosed psychological symptoms induced by the use of 
NPS.  
I – Intervention  
Which intervention, treatment or approach should be used? 
Any intervention for those using New Psychoactive Substances. 
C – Comparison 
What is/are the main alternative/s to compare with the intervention 
being considered? 
Use of no substance or use of another (non-NPS) illicit substance.  
O – Outcomes 
What is really important for the patient? Which outcomes should be 
considered? Examples include intermediate or short-term outcomes; 
mortality; morbidity and quality of life; treatment complications; 
adverse effects; rates of relapse; late morbidity and re-admission 
Critical to decision-making:  
Diagnosis of mental health condition(s) or psychological symptom(s). This could include NPS induced 
mental health conditions or exacerbation of symptoms of an existing mental health condition.  
Important to decision-making: 
 Impact of NPS on the clinical management of people living with mental health conditions.  
 Impact of NPS policy changes on mental health outcomes or wider outcomes of people living with 
existing mental health conditions.  
 Physical symptoms as a comorbidity to a mental health condition associated with NPS use.  
 
Assumptions / limits applied to search 
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Inclusion Criteria 
 
All dates included  
 
All peer reviewed literature included  
 
Exclusion Criteria None identified  
 
9. Search Strategy 
Search Terms: [NPS OR New Psychoactive Substances OR Novel Psychoactive Substances OR Legal Highs OR synthetic cannabinoids] 
AND [Mental health] 
Date: all date range  
Literature search databases: PubMed, The Cochrane Library, Elsevier..  
Search fields: Title and abstract 
 
10. Evidence selection  
 
 
 
 
 
Total 
papers 
identified 
by 
search: 
n = 480 
Papers 
excluded 
by title: 
n = 441 
Papers 
excluded 
by 
abstract 
review: 
n = 9 
Papers 
excluded 
by full text 
review: 
n = 11 
Papers 
included 
for 
review: 
 n = 19 
Relevant papers 
identified by 
working group 
members: n = 2 
Papers 
included 
for final 
review: 
n = 24 Relevant papers 
identified by PHE 
internal peer 
review: n = 3 
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Database Date of 
Search 
Search criteria 
Search 
results 
Papers 
excluded on 
title 
Papers 
excluded on 
abstract 
Papers for 
full text 
review 
PubMed 17/11/2016 (novel psychoactive substances[Title/Abstract]) OR new 
psychoactive substances[Title/Abstract])OR NPS 
[Title/Abstract])OR legal highs [Title/Abstract]) OR 
synthetic cannabinoids [Title/Abstract])AND mental 
health[Title/Abstract] 
52 40 2 10 
Cochrane 
Library 
18/11/2016 [Novel psychoactive substances OR new psychoactive 
substances OR NPS OR legal highs OR synthetic 
cannabinoids AND mental health] Title, abstract and key 
words 
21 21 0 0 
Elsevier 01/12/2016 TITLE-ABSTR-KEY(Novel psychoactive substances OR 
new psychoactive substances OR NPS OR legal highs OR 
synthetic cannabinoids ) and (Mental health or psychosis). 
8 0 3 5 
Public 
Health 
England 
04/01/2017 Novel psychoactive substances OR new psychoactive 
substances OR NPS OR legal highs OR synthetic 
cannabinoids AND mental health in Publication Titles OR 
Novel psychoactive substances OR new psychoactive 
substances OR NPS OR legal highs OR synthetic 
cannabinoids AND mental health in Abstract AND Novel 
psychoactive substances OR new psychoactive 
substances OR NPS OR legal highs OR synthetic 
cannabinoids AND mental health in Keywords 
399 380 4 15 
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